



3 December 2025

Control Bionics to Acquire Full Ownership in Neuro Elite Athletics and the NeuroBounce Program

Melbourne, Australia – Control Bionics Limited is pleased to announce that its U.S. subsidiary, **Control Bionics Ngage Inc. (“CBN”)**, has entered into an agreement (which remains subject to contract) to acquire the remaining **77.83%** of **Neuro Elite Athletics LLC**, the U.S. company behind the NeuroBounce athletic performance program.

Control Bionics made its initial investment in Neuro Elite Athletics in 2024. Since then, the NeuroBounce program - which combines neuromuscular activation strategies with measurable improvements in athletic explosiveness, muscle power and jumping capability - has continued to build interest across the **U.S. and Australia** as performance coaches and athletes explore EMG-driven tools to support improved activation and output.

Control Bionics Ngage will fund this acquisition through the issuance of shares in Control Bionics. Control Bionics will acquire full ownership for US\$389,150 and values Neuro Elite Athletics at US\$500,000. The total number of Control Bionics ordinary shares to be issued will be determined the day immediately before closing, based on the Company’s 5-day VWAP. Based on the closing share price of \$0.079 on 2 December, this would represent approximately 7.5m shares, or 1.9% of the issued capital.

These shares will be subject to a 12-month escrow.

The acquisition represents an important step in integrating the NeuroBounce offering more closely with Control Bionics’ NeuroStrip EMG technology platform and supports the Company’s strategy to expand into high-growth performance markets.

Upon completion, Neuro Elite Athletics will become a **wholly owned subsidiary** of Control Bionics. The acquisition will see Control Bionics acquire all of the intellectual property, staff and assets of Neuro Elite Athletics.

Completion is targeted for late **December 2025**, subject to confirmatory due diligence and execution of definitive documentation.

Control Bionics CEO, **Jeremy Steele**, said:

“NeuroBounce has shown promising early traction, and bringing the business fully into Control Bionics allows us to integrate it more tightly with our technology and commercial teams. This sets the foundation for faster rollout, deeper engagement with performance partners and a clearer pathway to growth in the U.S. and Australia.”

Neuro Elite Athletics Founder, Steve Bennett, said:

“This acquisition is the natural next step in what has already been an incredibly strong and productive partnership. For years, NeuroBounce and Control Bionics have shared a commitment to developing world-class, evidence-based technology that genuinely improves human performance and rehabilitation outcomes. Bringing our two 20-year-old businesses together allows us to fully integrate our complementary strengths, accelerate innovation, and deliver even greater

value to athletes, teams and coaches. I'm excited for what comes next as part of the Control Bionics family and intend to continue my work with the broader group."

This ASX announcement has been approved for release by the CEO of Control Bionics Limited.

For further information, please contact:

Investors and Media:

Jeremy Steele – CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley - Company Secretary
brettcrowley@controlbionics.com

Investor Relations:

Joe Durak
Executive Director & Founder
Lynx Advisors
joe@lynxadvisors.com.au
+61 414 465 582

For further information visit the website: <https://www.controlbionics.com/>

About Control Bionics:

Control Bionics is a medical device company that has more than 20 years' experience in the development and use of surface Electromyography (EMG) devices.

About NeuroNode:

Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

About NeuroStrip:

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Singapore and Japan.